Company Overview
BioAtla, Inc. operates as a clinical-stage biopharmaceutical entity focused on developing specific and selective antibody-based therapeutics designed for the treatment of solid tumor cancer. The company functions within the healthcare sector, specifically the biotechnology industry, where its primary objective is to advance novel biologics through the clinical development pipeline. As of the latest available data, the firm maintains a market capitalization of $12.69M and employs a workforce of 61 individuals dedicated to research and development. The market cap figure indicates a small-cap status relative to established pharmaceutical peers, while the absence of reported annual revenue highlights that the company is currently in a pre-revenue or early-stage commercialization phase typical for clinical-stage biotechnology firms.
Financial Health
The company reports a Net Income (TTM) of $-64,707,000 and an EBITDA of $-65,112,000, while revenue data is not available, suggesting that the significant gap between revenue and net income is driven entirely by substantial operational expenditures required to advance clinical trials rather than standard cost of goods sold. Free Cash Flow stands at $-32,930,750, which indicates that the company is burning cash to fund its clinical programs and that it currently lacks the financial flexibility to sustain operations without external capital raises or funding events. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the nature of the business model where revenue is not yet sufficient to cover the high fixed costs associated with drug development and clinical testing. The balance sheet shows a cash position of $8.32M against total debt of $6.18M, yet the Debt to Equity ratio is not available, likely due to the lack of shareholder equity value in a company with negative net income. Despite the cash on hand exceeding current debt obligations, the Current Ratio is 0.54, which signals that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity constraints. Return on Equity is not available given the equity structure, while Return on Assets is -105.1%, revealing that the company's assets are generating a negative return on an annualized basis, a common characteristic for early-stage biotechs that have not yet achieved commercial product milestones.
Valuation Assessment
Valuation multiples for the company are distorted by its lack of profitability, resulting in a P/E Ratio (TTM) that is not available and a Forward P/E of -0.11, which implies that the market is pricing in negative earnings expectations rather than a traditional earnings trajectory. The Price to Book ratio is -0.29, indicating that the company's market capitalization is below its book value, a scenario typical for firms with accumulated losses that have not yet generated positive equity. The Price to Sales ratio is listed as infinite, and the EV/EBITDA is -0.10, suggesting that traditional valuation multiples are not applicable and that investors must rely on alternative metrics such as cash runway or clinical trial milestones to assess value. The stock has traded within a 52-week range between a high of $1.43 and a low of $0.13, meaning the current price sits somewhere within this volatile band, subject to the inherent uncertainty of clinical-stage asset valuations. With a Beta of 1.08, the stock exhibits slightly higher volatility than the broader market, meaning price fluctuations are amplified relative to the S&P 500 index.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both not available due to the lack of historical revenue data and negative earnings, preventing a direct comparison of growth rates between sales and income. The company does not pay dividends, evidenced by a Dividend Yield of not available and a Payout Ratio of 0.0%, which confirms that all available cash is being retained and reinvested into the clinical development of its lead candidates rather than distributed to shareholders. Consequently, the growth profile is entirely dependent on the successful progression of its pipeline, specifically the lead clinical stage product candidate mecbotamab vedotin (BA3011), rather than income generation or shareholder returns. The overall growth and income profile is characterized by a reliance on external funding to bridge the gap between current cash reserves and the capital required to reach commercialization, with no current income stream to support a dividend policy.